The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.

source https://finance.yahoo.com/news/nabriva-nbrv-gains-fda-approval-204708170.html?.tsrc=rss